Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232844 | 0.86 | BRD4 (0.44) | BRD4MAPTLTA4H | |
| SCHEMBL25872172 | 0.83 | BRD4 (0.37) | BRD4CYP3A4CYP2C9CYP2C19TSHR | |
| SCHEMBL25872173 | 0.81 | MGAM (0.39) | BRD4MAPTTSHRKMT2AGAA | |
| SCHEMBL10232806 | 0.81 | BRD4 (0.42) | BRD4MAPTLTA4H | |
| SCHEMBL26465285 | 0.78 | BRD4 (0.58) | BRD4HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL18526232 | 0.78 | CYP1A2 (0.37) | MAPTTSHRMEN1KMT2A | |
| SCHEMBL17190309 | 0.78 | ALDH1A1 (0.32) | — | |
| SCHEMBL26890000 | 0.76 | BRD4 (0.39) | BRD4MAPTLTA4H | |
| SCHEMBL9683068 | 0.76 | KMT2A (0.46) | BRD4MAPTKMT2ALTA4HNR1H2 | |
| SCHEMBL18705049 | 0.76 | CHRM5 (0.39) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| WO-2023072257-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192688-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF | EGLN3, EGLN2, EGLN1 | BRD4 161/4885HSD17B10 327/4885CYP3A4 3608/4885 |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN3, EGLN2, EGLN1 | BRD4 161/4885HSD17B10 327/4885CYP3A4 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.